Price
$13.50+23.40%Social Signal Score
Analyst Ratings
10 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jacob Chacko
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 111
- Beta
- 0.99
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 29.23
Financials
Net Income
$-41.49MEBITDA
$-45.03MFree Cash Flow
$-31.96MEPS (diluted)
$-0.38Shares Outstanding (diluted)
108.01M+464.3%Operating Expenses
$45.30MCash & Debt
$264.76MReturn of Capital
$1.25MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-129.47M | $-1.47 |
| 2024 | $0.00 | $-127.85M | $-1.83 |
| 2023 | $0.00 | $-100.70M | $-1.96 |
| 2022 | $0.00 | $-89.12M | $-2.25 |
| 2021 | $0.00 | $-78.72M | $-2.07 |
| 2020 | $0.00 | $-73.70M | $-3.36 |
| 2019 | $0.00 | $-26.88M | $-1.40 |
| 2018 | $0.00 | $-21.36M | $-12.32 |
| 2017 | $0.00 | $-22.03M | $-15.62 |
Valuation
ORIChas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60-40.00%Social Signal Score
Mentions (6)
- Newsglobenewswire.com·17h ago·Negative
ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development ORIC-259 is a potential first-in-class small molecule mRNA degrader targeting CIP2A, a previously undruggable target Cancer Research UK to fully fund, sponsor, design, and execute CTA-enabling studies and Phase 1/2 clinical development ORIC retains exclusive option to reacquire rights to ORIC-259 following Phase 1/2 data SOUTH SAN FRANCISCO, Cal…
View source ↗ - Newsglobenewswire.com·3d ago·Neutral
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on October 1, 2026 (the “Grant Date”), ORIC granted a total of 161,550 non-qualified stock options and 26,850 restricted stock units to six new non-executive …
View source ↗ - Newsseekingalpha.com·20d ago·Positive
ORIC Pharmaceuticals, Inc. (ORIC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript ORIC Pharmaceuticals, Inc. (ORIC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·31d ago·Neutral
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept.
View source ↗ - Newsglobenewswire.com·33d ago·Neutral
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced that management will be participating in the following investor conferences in September:
View source ↗ - Newsglobenewswire.com·59d ago·Neutral
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on August 3, 2026 (the “Grant Date”), ORIC granted a total of 125,400 non-qualified stock options and 20,550 restricted stock units to five new non-executive
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.40 per share
Typical surprise +1.9% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 3$-0.38 vs $-0.36miss
- Mon, May 4$-0.34 vs $-0.32miss
- Mon, Feb 23$-0.30 vs $-0.34beat
- Thu, Nov 13$-0.33 vs $-0.41beat
- Tue, Aug 12$-0.47 vs $-0.46miss
- Mon, May 5$-0.42 vs $-0.51beat
Estimates and results for ORIC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ORIC officers and directors.
- Bought
- $263k
- Sold
- $6.5m
2 trades
31 trades
- Heyman Richard A.sold
- Heyman Richard A.sold
- Piscitelli Dominicsold
- Piscitelli Dominicsold
- Piscitelli Dominicsold
- Piscitelli Dominicsold
- Heyman Richard A.sold
- Heyman Richard A.sold
67 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ORIC.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.